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Abstract 
 
 
 
 
 
 
 
Gastrointestinal stromal tumors (GIST) are somewhat rare gastrointestinal tumors - 
approximately 1% to 3% incidence, but they are the most common mesenchymal neoplasms 
of the gastrointestinal tract. GISTs are usually found in the stomach or small intestine but 
can occur anywhere within the gastrointestinal tract, even in extremely uncommon locations 
like duodeno-jejunal flexure. Only 3% – 5% of GISTs are located in the duodenum and 
tumors occurring in the angle of Treitz are even rarer, most published studies being case 
reports. These tumors have a size ranging from small lesions to large masses and can cause 
digestive bleeding or high bowel obstruction.  
This paper is a case presentation illustrating an emergency situation involving a high 
bowel obstruction caused by a small tumor with an unusual location in the Treitz’s angle. A 
large percentage of duodenal GISTs are localized in the third and fourth part of the 
duodenum and may not be found through standard upper endoscopy; only the barium study 
of the upper gastrointestinal tract highlights the obstruction point. Preoperative diagnosis is 
difficult but non-invasive imaging techniques like ultrasonography and computed 
tomography of the abdomen can be helpful.  Recently, targeted therapy with inhibitors of 
tyrosine kinase receptors (IMATINIB) has been introduced for the management of 
advanced and metastatic tumors. In our opinion the surgical resection with curative intent is 
the treatment of choice. 
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Introduction 
The first authors that coined the term GIST 
were Mazur and Clarke in 1983, referring to distinct 
mesenchymal tumors that lack features 
characteristic of smooth muscles differentiation (1). 
In 1998, Kindblom et al. demonstrated that the 
actual origin’s cell of these tumors is a pluripotent 
mesenchymal stem cell programmed to differentiate 
into interstitial cells of Cajal, the gastrointestinal 
tract "pacemaker cells" - the cells responsible for 
initiating and coordinating gastrointestinal motility 
(2). The most important development that made 
GIST a unique clinical entity was the discovery of 
c-kit proto-oncogene in these tumors by Hirota and 
colleagues in 1998 (3). C-KIT has been 
demonstrated as a very specific and sensitive 
marker, with about 95% of GISTs express c-KIT. 
Usually, GISTs appear in middle age, 
affecting males and females equally. They rarely 
occur in children or young adults, but when they do, 
an association with neurofibromatosis and Carney's 
triad (gastric stromal tumor, extra adrenal 
paraganglioma and pulmonary chordoma) has been 
noted (4). 
A GIST can be located anywhere in the 
gastrointestinal tract. Small intestinal tumors occur 
in 20-30% of digestive tract tumors; duodenal 
tumors occur less than 5%. Tumors occurring in the 
angle of Treitz are even rarer, with most published 
studies being case reports (5). Most such cases 
occur sporadically, but some may occur in the 
context of a familial syndrome (Peutz-Jeghers 
syndrome or Crohn’s disease) (6). Patients with 
duodenal GIST have the symptoms such as 
abdominal pain, iron-deficiency anemia, 
gastrointestinal bleeding, or vomiting caused by an 
obstruction. A tumor of the angle of Treitz may also 
be an incidental finding during clinical 
examination. 
Limited surgical resection or pancreatico-
duodenectomy is the treatment of choice (7). Most 
tumors located at the angle of Treitz are 
gastrointestinal stromal tumors (GISTs) and only a 
few are adenocarcinomas.  
From our broad experience with tumors 
located at the level of Treitz angle (10 cases 
reported so far), we selected this one for detailed 
analysis as it manifested as a GIST during 
immunochemistry exams. Although the surgical 
approach was optimal and the general outcome 
positive, this type of tumor poses challenges for the 
surgeon and raises several interesting points for 
discussion. 
 
Material and Methods 
This paper presents the case of a female 
patient, G.S., 54 years old, who was admitted to our 
clinic, Witting Clinical Hospital, General Surgery 
Department, for persistent abdominal pain in the 
epigastrium and left hypochondrium associated 
with asthenia, pallor of skin, weight loss of about 5 
kg.; symptoms occurred within the past 6 months. 
These symptoms were accompanied in the last 16 
hours by nausea and vomiting. The patient’s history 
was negative for alcohol, tobacco, or illicit drug use 
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and her family history was unremarkable. The 
patient had no surgical history and was under 
treatment for hypertension (maximum value 
195/110 mmHg) with Bisoprololum 10mg (1 tablet 
daily), Quinalaprilum 10 mg (2 tablets daily), and 
Acetylsalicylic Acidum 75 mg (1 tablet daily). 
 
 
Figure 1. Barium study of the upper gastrointestinal 
tract filling defect of the fourth portion of the duodenum 
with dilated stomach and duodenum proximal to the site 
of obstruction and gastroesophageal reflux without 
radiological signs of hiatal hernia. 
On physical examination the patient was 
found under weight, pale and with tachycardia 
(pulse rate – 110/min, blood pressure – 130/85 
mmHg; the belly was mobile with respiratory 
movements, painful spontaneous and on palpation 
in epigastrium, without palpable mass; auscultation 
revealed normal bowel sounds and the bowel was 
preserved. Rectal exam was normal. 
 
 
Figure 2. Intraoperative image 2 cm. diameter 
circumscribed mass in the fourth part of duodenum, 
developed in the lumen, with important distension of the 
stomachand duodenum 
Blood tests revealed a hemorrhagic anemia 
(Hgb = 8,2 gm/dl, Hct = 29,9% and MCV, MCH, 
MCHC in low levels), iron deficiency (serum iron = 
36 mcg/dl), positive fecal occult blood test, slightly 
altered kidney function (BUN = 60 mg/dl, 
Creatinine = 1,34 mg/dl); other blood tests were 
within normal limits, including the levels of tumor 
markers (CEA, CA 19–9, α-fetoprotein). 
After nasogastric tube positioning, the upper 
endoscopy revealed dilated hypotonic stomach and 
duodenum with lesions of erosive gastritis and 
duodenitis. Using barium study of the upper 
gastrointestinal tract, we found a filling defect of 
the fourth portion of the duodenum, with dilated 
stomach and duodenum proximal to the site of 
obstruction; we also found gastroesophageal reflux 
without radiological signs of hiatal hernia (Figure 
1). Ultrasonography and CT scan showed no 
metastases. 
Surgery was recommended after correcting 
the anemia and electrolyte balance. A midline 
laparotomy was chosen, revealing a tumor of about 
2 cm in diameter, with a circumscribed mass shape 
was found at the fourth part of the duodenum, 
developed mostly in the lumen, with extensive 
mesenteric fibrosis in the near of the Treitz’ angle 
and important distension of the stomach and 
duodenum. No macroscopic involvement of 
regional lymph nodes or liver and no direct invasion 
of the pancreas had occurred (Figure 2). 
The tumor was resected with 5 cm of 
uninvolved duodenal margins, and an end-to-side 
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anastomosis was performed between the descending 
duodenum and the proximal jejunum (Figure 3). 
Access to the third and fourth part of the duodenum 
was gained by complete mobilization of the Treitz’s 
angle from the left side of the proximal jejunum to 
the right side of the angle, by cutting the ligament 
of Treitz.  
The histological examination of the 
specimen demonstrated an intramural small tumor - 
2 cm in diameter with intraluminal growth and 
obstruction. The final diagnosis was a high-grade 
ulcerated GIST with classic spindle cells, clear 
resection margins and no lymph node invasion 
(Figure 4). Mitotic activity was 12/50 on HPF 
(High-Power Fields). Ki67 proliferation marker 
labels 10% of the nuclei (Figure 5). 
Immunohistochemistry was positive for 
CD117/c-kit and CD34 immunomarkers (Figure 6) 
and negative for desmin, vimentin, muscle-
specificactin, smooth muscle actin, S-100protein 
and neuron-specific enolase. 
The patient’s postoperative course passed 
without any problems. An oncologist colleague 
started adjuvant treatment with inhibitors of 
tyrosine kinase receptors – IMATINIBMESYLATE 
400mg once daily for 2 years. 
The patient is disease-free after a 1.5 year 
follow-up. A recent barium gastrointestinal follow 
up study demonstrated a widely patent anastomosis 
with a normal mucosal pattern between the 
proximal duodenum and jejunum (Figure 7) and 
ultrasoudsonography and CT scan do not highlight 
pathological lesions. 
 
 
 
Figure 3. Intraoperative image after resection of the 
tumor, the end-to-side anastomosis between the 
descending duodenum and the proximal jejunum 
 
Discussion 
The maximum incidence places GIST at 
gastric level (50% - 70%) and small intestine (20%-
30%), being followed by colon and rectal locations 
(10%), epi-ploon and mesenteric areas, esophagus 
(5%) and retroperitoneal space (5%). As already 
pointed out, duodenal tumors occur less than 5%, 
and tumors occurring in the angle of Treitz are even 
rarer (5). 
The epidemiology of GISTs cannot be 
completely estimated. The average age of patients 
with GISTs is 53 years and only 5% are under the 
age of 30. Duodenal GISTs commonly involve the 
second part of the duodenum followed by the third, 
fourth, and first part (8). 
Duodenal GISTs are relatively small in size, 
with the median reported to be 4 cm in contrast to 
the median of gastric and small intestinal GISTs of 
6 to 7 cm, respectively. Duodenal GISTs that are 
detected early when they are smaller are amenable 
to relatively minor resection or excisional surgery. 
They may also have a favorable prognosis in 
comparison to GISTs from other sites of the 
gastrointestinal tract (8).  
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Figure 4. Microscopic finding bundles of spindle cells 
with elongated nuclei and significant mitotic activity (H & 
E staining; 100x optical magnification) 
 
 
Figure 5. Microscopic finding exhibiting a positive 
immunohistochemistry for Ki 67 (Ki67 staining; 40x 
optical magnification) 
 
 
Figure 6. Microscopic finding immunohistochemistry 
exhibiting a strong positive for CD117 (CD117 staining; 
optical magnification of 40x). 
Patients with duodenal GIST have the 
symptoms that may include abdominal pain, iron-
deficiency anemia, gastrointestinal bleeding, 
obstructive jaundice, palpable mass or vomiting 
caused by an obstruction. In our case, a high bowel 
obstruction was caused by the tumor with location 
in the Treitz’s angle, but we note a previous six 
month evolution of gastrointestinal bleeding and 
iron-deficiency anemia. A tumor of the angle of 
Treitz may also be an incidental finding. 
A large percentage of duodenal GISTs are 
localized in the third and fourth part of the 
duodenum and may not be found through standard 
upper endoscopy. Intraluminal growth is visualized 
on barium radiography as a distinct, smooth filling 
defect; ulceration or depression at the peak of the 
protrusion can be observed. Endoscopic ultrasound 
is helpful when the tumors are submucosal or arise 
from an intramural or extramural structure (9, 10). 
CT scan and MRI are the optimal imaging tests for 
description of the primary lesion, the local 
extension, and metastasis. 
Surgical treatment represents one of the 
most efficient approaches to cure a GIST. The 
possibility of a real, life-saving resection gives 
these types of tumors a positive overall prognosis. 
This trend for a positive outcome remains even 
when there is local spread to adjacent organs if a 
true radical and complex excision is performed 
during the initial surgery. However, this is not the 
case for a GIST that has already become metastatic; 
a different clinical outcome should be expected, 
with a very low survival rate.  
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Figure 7. Follow-up barium study of the upper 
gastrointestinal tract widely patent anastomosis with a 
normal mucosal pattern betweenthe proximal duodenum 
and jejunum 
The tumor relapse rate or the possibility of a 
metastatic behavior occurs in about 50% of cases, 
even if radical excision of the primary tumor is 
performed; the responsible factors include: tumor 
fracture during intraoperative manipulation or 
performing a palliative resection or even a sub-
standard so-called extended resection, with remnant 
margins positive for tumoral traces. 
Primary tumor resection allows for a 
survival rate of about one year from the main 
surgery, and the main sites for tumoral relapse are 
the liver, the great omentum and the peritoneal 
surface. The basic rules of classic oncologic surgery 
should be applied with the utmost attention, such as 
tumoral-free remnant margins, a monolith-like 
dissection that takes into the same block the primary 
tumor and its local spread to the nearby organs, 
avoidance of the peritoneal pollution with tumor 
debris, and minimizing the lymphatic resection, since 
these tumors do not take the lymphatic route for a 
wide metastatic spread. 
All GISTs are considered as malignant, even 
the intramural with a diameter of less than 2 cm, 
and therefore should be resected; in this regard, a 
laparoscopic approach is allowed. 
The evolution of GIST tumors has been 
estimated, based on studies considering a 
combination of clinical and anatomo-pathological 
factors. Strong evidence demonstrates these tumors 
are influenced by their location within the digestive 
tract. Thus, the tumors located at the level of the 
small bowel tend to develop a malignant action 
more frequently than gastric tumors, and tumors 
developing at the level of the colon or rectum tend 
to display a more metastatic behavior. Some 
studies, based on a large scale clinical research, 
point out some markers for a severe prognosis: 
aneuploidy (proven by the means of flux-
cytometry): size of the tumor, coagulation based 
necrosis, a low score for Ki67 marker and 
peritoneal spreading during the initial surgery (11, 
12). 
At the time of their first diagnosis, almost 
25%-30% of all GISTs are malignant as the feature 
secondary metastasis (most often at the level of 
liver) or are spread locally. As malignant evolution 
is unpredictable and benign development is less 
likely, the rest of the tumors have been approached 
with different levels of medical aggression. 
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In surgical practice, when we discuss the 
risk of aggressivity, we take into consideration both 
the size of the tumor and its mitotic index. 
Therefore we now recognize GISTs that are rated as 
very low, low, intermediate, or high risk of 
aggression, based on their potential of developing 
metastases and relapse (13). 
Benign characteristics of these tumors are: a 
size less than 5 cm of the tumor, a low mitotic index 
of less than 5 mitoses per 20 High Power Field, 
Nikon technology, a 40x optical magnification, a 
10x objective. The mitotic index is interpreted in 
close relationship with the cellular type, nuclear 
modifications, and cellularity. 
Targeted therapy with inhibitors of tyrosine 
kinase receptors (IMATINIB) has been introduced 
for the management of advanced and metastatic 
tumors. Primary resistance of these tumors to the 
Imatinib™ is noted at about 5%, and secondary 
resistance develops due to some second-stage 
mutations of the tirozin-kinazic receptor (14-16); a 
possible way to work around this problem is to 
increase the 24 hr dosage or the surgical 
intervention to remove the remnant tumor. Some 
authors cite partial clinical resistance with a 
remission of a tumor clone while other tumors yet 
develop. 
Sometimes simple resection with a free 
margin of about 2 cm provides the edge necessary 
to defeat the malignant evolution of a case and 
provide full recovery with no relapse at the 5-year 
mark. 
Conclusions 
Based on our experience, the reasons behind 
the rarity of gastrointestinal stromal tumors could 
reside in one or all the following: the high speed of 
the digestive transit, the alkaline pH of the small 
bowel, the reduced bacterial population diversity 
and concentration in the small bowel, less 
aggressive liquid content of the small bowel, high 
concentration of IgA at this level, with a proven 
local protective role and, finally, a high content of 
benzipren-hidroxylaze enzyme with high 
anticarcinogenetic potential. 
Surgical resection is the primary treatment 
for GIST tumors and the only therapy offering a 
chance of cure, although there is evidence that 
IMATINIB-based therapy has significant potential. 
GISTs located at the level of duodenum 
appear slow-growing and exhibit a limited 
propensity for both metastatic and local spread; 
such favorable biologic characteristics mandate an 
aggressive surgical approach to this disease, aimed 
at complete tumor excision with negative histologic 
margins. 
The location and histology of the tumors 
permitted a pancreas-preserving segmental 
duodenectomy, a real benefit for a tumor located at 
the level of Treitz’s angle, the operative approach 
chosen allowing the patient to develop very well in 
the postoperative stage with a general favorable 
outcome in the long term. 
One of the goals of this paper was to 
showcase an extremely rare tumor located at an 
extremely rare level of the small bowel that could 
well end up in a diagnosis trap. Also, the rarity of 
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these cases, their evolutive particularities, survival 
rate, the histopathological or immunohistochemistry 
aspects, and the therapeutic plan are points of equal 
interest for this study as well. 
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ACRONYMS AND ABBREVIATIONS 
 
GISTs: Gastrointestinal stromal tumors  
GI: Gastrointestinal 
CD 117/c-kit: Cluster of differentiation 117/proto-
oncogene c-kit  
CD 34: Cluster of differentiation 34 
KIT: Tyrosine-protein kinase 
CA 19–9: Carbohydrate antigen 19–9 
CEA: Carcinoembryonic antigen 
PDGFRa: Platelet-derived growth factor receptor  
CT scan: Computer tomography scan 
MRI: Magnetic resonance imaging 
 
References 
1. Mazur MT, Clark HB. Gastric stromal tumors. 
Reappraisal of histogenesis. The American 
Journal of Surgical Pathology 1983; 7(6): 507-
19. 
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-
Kindblom JM. Gastrointestinal pacemaker cell 
tumor (GIPACT): gastrointestinal stromal 
tumors show phenotypic characteristics of the 
interstitial cells of Cajal. The American Journal 
of Pathology 1998; 152(5): 1259-69. 
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, 
Nishida T, Ishiguro S, Kawano K, Hanada M, 
Kurata A,. Gain-of-function mutations of c-kit in 
human gastrointestinal stromal tumors. Science 
1998; 279(5350): 577-80. 
4. Miettinen M, Sarlomo-Rikala M, Lasota J. 
Gastrointestinal stromal tumors: Recent 
advances in understanding of their biology. 
Human Pathol. 1990; 30(10): 1213-20. 
5. Maglio R, Valabrega S, Ramacciato G. 
Duodenal carcinoma at ligament of Treitz. Case 
report and review of the literature. Il Giornale di 
Chirurgia. 2012; 33(5): 179-81. 
6. Xie YB, Liu H, Cui L, Xing GS, Yang L, Sun 
YM, Bai XF, Zhao DB, Wang CF, Tian YT. 
Tumors of the angle of Treitz: a single-center 
experience. World Journal of Gastroenterology. 
2014; 20(13): 3628-34. 
7. De Vogelaere K, Van De Winkel N, Aerts M, 
Haentjens P, Spitali C, Van Loo I, et al. Surgical 
Gastrointestinal stromal tumor (GIST) of the Treitz’s angle 
202 
 
management of gastrointestinal stromal tumours: 
a single centre experience during the past 17 
years. Acta chirurgica Belgica. 2014; 114(3): 
167-73. 
8. Mokhtare M, Taghvaei T, Tirgar Fakheri H. 
Acute bleeding in duodenal gastrointestinal 
stromal tumor. Middle East Journal of Digestive 
Diseases. 2013; 5(1): 47-51. 
9. Araujo T, Castro-Pocas F, Santos M, Coelho A, 
Lago P, Pedroto I. Endoscopic ultrasound, GIST, 
and ovarian cancer. International Journal of 
Colorectal Disease. 2015; 30(7): 991. 
10. Tsuji Y, Kusano C, Gotoda T, Itokawa F, 
Fukuzawa M, Sofuni A, et al. Diagnostic 
potential of endoscopic ultrasonography-
elastography for gastric submucosal tumors: A 
pilot study. Digestive endoscopy: Official 
Journal of the Japan Gastroenterological 
Endoscopy Society. 2016; 28(2): 173-8. 
11. Ungureanu FD. Curs de Chirurgie. In: Titu 
Maiorescu Editor. Patologia chirurgicala a 
esofagului Patologia chirurgicala a intestinului 
subtire, 1. Bucharest 2012. p. 145-53. 
12. de Oliveira RP, Portari Filho PE, Iglesias AC, de 
Oliveira CA, Pannain VL. Comparative study of 
the different degrees of risk of gastrointestinal 
stromal tumor. Revista do Colegio Brasileiro de 
Cirurgioes. 2015; 42(1): 32-6. 
 
 
 
13. Agaimy A. Gastrointestinal stromal tumors 
(GIST) from risk stratification systems to the 
new TNM proposal: more questions than 
answers? A review emphasizing the need for a 
standardized GIST reporting. International 
Journal of Clinical and Experimental Pathology. 
2010; 3(5): 461-71. 
14. Das D, Ganguly S, Deb AR, Aich RK. 
Neoodjuvant imatinib mesylate for advanced 
primary and metastactic/recurrent gastro-
intestinal stromal tumour (GIST). Journal of the 
Indian Medical Association. 2013; 111(1): 21-3. 
15. DeMatteo RP, Ballman KV, Antonescu CR, 
Corless C, Kolesnikova V, von Mehren M, 
McCarter MD, Norton J, Maki RG, Pisters PW, 
Demetri GD, Brennan MF, Owzar K; American 
College of Surgeons Oncology Group 
(ACOSOG) Intergroup Adjuvant GIST Study 
Team for the Alliance for Clinical Trials in 
Oncology. Long-term results of adjuvant 
imatinib mesylate in localized, high-risk, 
primary gastrointestinal stromal tumor: 
ACOSOG Z9000 (Alliance) intergroup phase 2 
trial. Annals of Surgery. 2013; 258(3): 422-9. 
16. Garcia del Muro X. Nilotinib, imatinib, and 
GIST therapy. The Lancet Oncology 2015; 
16(5): 483-4.  
 
